Navigation Links
The First Direct Structural Evidence of SV2A has Been Revealed Thanks to Protein Tomography(TM), and Published in BBRC
Date:9/9/2008

Summary: Protein Tomography(TM) has yet Again Provided Structural Proof of a Drug Target Function. A Study Performed by Sidec and UCB, Characterizes the Target of Anti-Epileptic Drug in Situ Where Two Major Conformations

Have Been Identified

STOCKHOLM, September 9 /PRNewswire/ -- Sidec AB has together with UCB published the first direct structural evidence of the molecular mechanism of the Synaptic Vesicle protein 2A (SV2A) in mouse brain tissue. SV2A is the unique brain-binding site of the second generation anti-epileptic drug levetiracetam (LEV; Keppra(R) is a trademark of UCB). The result shows the first direct structural proof of the "alternating access model" that has been proposed for the MFS class of transporter proteins. The "alternating access model" postulates that the trans-membrane MFS class proteins can exist in two different conformations; as a valve that can be open to either side of the membrane. Prior to this Protein Tomography(TM) study, great efforts were made to prove this mechanism both by x-ray crystallography and indirectly by site directed mutagenesis.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080220/294289 )

"Obtaining structures of trans-membrane proteins is notoriously difficult, and the success of such endeavours is difficult to predict. This study demonstrates that Protein Tomography(TM) is well adopted to study structure, function and flexibility of trans-membrane proteins," says Anders Aberg, CSO at Sidec.

The publication is available on-line in the journal Biochemical and Biophysical Research Communications, August 7, 2008. http://www.elsevier.com/locate/ybbrc

About Sidec:

Sidec offers Protein Tomography((TM)) as collaborative contract research projects. The multidisciplinary team of experts at Sidec can provide a strong IP strategy and proven product differentiation to the bio-pharmaceutical industry. Sidec offers their partners a unique visual guidance for target- lead and CD selection to secure a competitive advantage in the drug design strategy. More information can be found on our homepage where we continuously update academic collaborations and industrial partnerships as well as recent publications.

For more information, please contact:

Mr. Hans Johansson, CEO

Phone: +46(8)560-02-102

E-mail: hans.johansson@sidec.com

http://www.sidec.com


'/>"/>
SOURCE Sidec AB
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Sixty-One Percent of Newly Diagnosed Parkinsons Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
3. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
4. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
5. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
6. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
7. Tainted Chinese Food Ingredients First Discovered in 2005
8. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
9. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
10. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
11. Opko Health Doses First Patient in Phase 3 COBALT Trial of Bevasiranib for the Treatment of AMD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... , June 23, 2016 Research ... Pharma News Issue 52" report to their offering. ... in influenza treatment creates a favourable commercial environment for MedImmune ... growing patient base that will serve to drive considerable growth ... vaccine would serve to cap sales considerably, but development is ...
(Date:6/23/2016)... Revolutionary technology includes multi-speaker listening ... industry leaders in advanced audiology and hearing aid technology, ... ™, the world,s first internet connected hearing aid that ...      (Photo: http://photos.prnewswire.com/prnh/20160622/382240 ) , ... ,world firsts,: , TwinLink™ - the first ...
Breaking Medicine Technology:
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
Breaking Medicine News(10 mins):